Perrigo Company plc Restructuring Costs and Asset Impairment Charges
Perrigo Company plc (PRGO) reported Restructuring Costs and Asset Impairment Charges of $17.90 million for the 9-month period ending 2016-10-01, per its 10-Q/A filed 2017-05-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2017-05-23
- Perrigo Company plc restructuring costs and asset impairment charges for the quarter ending 2016-10-01 was $6.60M, a 200.00% increase year-over-year.
- Perrigo Company plc restructuring costs and asset impairment charges for the quarter ending 2016-07-02 was $5.90M.
- Perrigo Company plc restructuring costs and asset impairment charges for the quarter ending 2016-04-02 was $5.40M, a 390.91% increase year-over-year.
- Perrigo Company plc restructuring costs and asset impairment charges for the quarter ending 2015-12-31 was $24.70M, a 888.00% increase year-over-year.
- Perrigo Company plc restructuring costs and asset impairment charges for fiscal 2015 was $5.10M, a 89.15% decline from fiscal 2014.
- Perrigo Company plc restructuring costs and asset impairment charges for fiscal 2014 was $47.00M, a 1520.69% increase from fiscal 2013.
- Perrigo Company plc restructuring costs and asset impairment charges for fiscal 2013 was $2.90M, a 66.67% decline from fiscal 2012.
- Perrigo Company plc restructuring costs and asset impairment charges for fiscal 2012 was $8.70M.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 9 month | Restructuring Costs and Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2016-10-01 | $6.60M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-05-23 | $12.50M derived: sum of 2 quarters · filed 2017-05-23 | $17.90M 10-Q/A · filed 2017-05-23 | $42.60M derived: sum of 4 quarters · filed 2017-05-23 |
| 2016-07-02 | $5.90M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-05-22 | $11.30M 10-Q/A · filed 2017-05-22 | $36.00M derived: sum of 3 quarters · filed 2017-05-22 | $38.20M derived: sum of 4 quarters · filed 2017-05-22 |
| 2016-04-02 | $5.40M 10-Q/A · filed 2017-05-22 | $30.10M derived: sum of 2 quarters · filed 2017-05-22 | $32.30M derived: sum of 3 quarters · filed 2017-05-22 | $32.20M derived: sum of 4 quarters · filed 2017-05-22 |
| 2015-12-31 | $24.70M derived: 10-KT 6 month − 10-Q 3 month · filed 2016-02-25 | $26.90M 10-KT · filed 2016-02-25 | $26.80M derived: sum of 3 quarters · filed 2017-05-22 | $27.90M derived: sum of 4 quarters · filed 2017-05-22 |
| 2015-09-26 | $2.20M 10-Q · filed 2015-11-02 | $2.10M derived: sum of 2 quarters · filed 2017-05-22 | $3.10M 10-Q/A · filed 2017-05-23 | $5.70M derived: sum of 4 quarters · filed 2017-05-22 |
| 2015-06-27 | -$100.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-05-22 | $1.00M 10-Q/A · filed 2017-05-22 | $3.50M derived: sum of 3 quarters · filed 2017-05-22 | $5.10M 10-KT · filed 2016-02-25 |
| 2015-03-28 | $1.10M 10-Q/A · filed 2017-05-22 | $3.60M derived: sum of 2 quarters · filed 2017-05-22 | $5.30M 10-Q · filed 2015-04-29 | $34.70M derived: sum of 4 quarters · filed 2017-05-22 |
| 2014-12-27 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-05 | $4.20M 10-Q · filed 2015-02-05 | $33.60M derived: sum of 3 quarters · filed 2016-02-25 | $36.90M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-09-27 | $1.70M 10-Q · filed 2015-11-02 | $31.10M derived: sum of 2 quarters · filed 2016-02-25 | $34.40M derived: sum of 3 quarters · filed 2016-02-25 | $46.80M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-28 | $29.40M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25 | $32.70M derived: sum of 2 quarters · filed 2016-02-25 | $45.10M derived: sum of 3 quarters · filed 2016-02-25 | $47.00M 10-KT · filed 2016-02-25 |
| 2014-03-29 | $3.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-29 | $15.70M derived: sum of 2 quarters · filed 2015-04-29 | $17.60M 10-Q · filed 2015-04-29 | |
| 2013-12-28 | $12.40M derived: 10-Q 6 month − 8-K 3 month · filed 2015-02-05 | $14.30M 10-Q · filed 2015-02-05 | ||
| 2013-09-28 | $1.90M 8-K · filed 2014-11-20 | |||
| 2013-06-29 | $2.90M 10-KT · filed 2016-02-25 | |||
| 2012-06-30 | $8.70M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |